RxDoctor Payments Data

Julia Turchaninov, PA

Physician Assistant · Phoenix, AZNPI 1710231030

Payments from drug & device makers

$3,129in general payments, 2019–2025

Across 201 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$393
  • Nestle Healthcare Nutrition Inc.$171
  • Aimmune Therapeutics, Inc.$149
  • Johnson & Johnson$124
  • GSK$117
  • plus $912 from 21 others

What the payments were for

  • Food & beverage$3,11099%
  • Entertainment$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,129 in reported general payments places this provider in the 85th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$56,347
Medicare patients
167
Services billed
686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase23$61,611
VascepaIcosapent Ethyl52$54,115
OzempicSemaglutide35$46,261
FarxigaDapagliflozin Propanediol27$43,066
EliquisApixaban25$39,356
ZenpepLipase/Protease/Amylase12$36,459
LinzessLinaclotide21$28,514
JanuviaSitagliptin Phosphate21$14,798
XareltoRivaroxaban12$12,055
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,900
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,641
Ursodiol14$4,434
Rosuvastatin Calcium62$3,156
SymbicortBudesonide/Formoterol Fumarate11$2,632
Pregabalin12$2,299

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,263$90,12544 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$393$52,33949 claims
Novo NordiskOzempic$97$46,26135 claims
PfizerEliquis$36$39,35625 claims
Aimmune Therapeutics, Inc.Zenpep$149$36,45912 claims
Johnson & JohnsonXarelto$124$12,05512 claims
GSKTrelegy Ellipta$117$6,90011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →